KR960700046A - 녹내장 치료 방법(glaucoma treatment) - Google Patents

녹내장 치료 방법(glaucoma treatment) Download PDF

Info

Publication number
KR960700046A
KR960700046A KR1019950702259A KR19950702259A KR960700046A KR 960700046 A KR960700046 A KR 960700046A KR 1019950702259 A KR1019950702259 A KR 1019950702259A KR 19950702259 A KR19950702259 A KR 19950702259A KR 960700046 A KR960700046 A KR 960700046A
Authority
KR
South Korea
Prior art keywords
antagonist
glutamate
stimulatory
glaucoma
toxicity
Prior art date
Application number
KR1019950702259A
Other languages
English (en)
Inventor
스튜어트 에이. 립턴
에반 비. 드레이어
Original Assignee
에프, 커티스 스미쓰
매사츄세츠 아이 앤드 이어 인퍼머리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프, 커티스 스미쓰, 매사츄세츠 아이 앤드 이어 인퍼머리 filed Critical 에프, 커티스 스미쓰
Publication of KR960700046A publication Critical patent/KR960700046A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명에 따르면, 글루타메이트 레벨의 증가는 녹내장과 관련이 있으며, 망막의 신경절 세포에 대한 손상은 글루타메이트에 의해 유도된 자극 독성을 감소시킬수 있는 화합물을 상기 자극 독성을 감소시키기에 효과적인 양으로 환자에게 투여함으로써 조절할 수 있다.

Description

녹내장 치료 방법(GLAUCOMA TREATMENT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 대조용 초자체와 비교한 녹내장 초자체에서의 정상적인 아미노산 농도의 막대 그래프이다.
제2도는 녹내장 년수의 함수로서 플로팅한 초자체내 글루타메이트 아미노산 농도의 그래프이다.

Claims (23)

  1. 비혈관형 녹내장과 관련된 망막 신경질 세포에 대한 손상으로부터 인간환자를 보호하는 방법으로서, 글루타메이트에 의해 유도된 자극 독성의 길항물질을 함유하는 약을 상기 자극 독성을 감소시키기에 효과적인 농도로 상기 환자에게 투여하는 것을 포함하며, 이때, 상기 길항물질은 혈액-뇌장벽 및 혈액-망막 장벽을 통과할 수 있는 방법.
  2. 인간 환자에게 녹내장 관련 손상에 대해 망막 신경질 세포를 보호하는 방법으로서, 글루타메이트에 의해 유도된 자극 독성의 길항물질을 함유하는 약을 상기 자극 독성을 감소시키기에 효과적인 농도로 상기 환자에게 투여하는 것을 포함하여, 이때, 길항물질은 L-형 전위 의존성 Ca++채널에 직접적인 효과를 거의 미치지 않는 것을 특징으로 하는 방법.
  3. 비혈관형 녹내장과 관련된 망막 신경질 세포에 대한 손상으로부터 인간환자를 보호하는 약의 제조 방법으로서, 이 약은 글루타메이트에 의해 유도된 자극 독성의 길항물질을 상기 자극 독성을 감소시키기에 효과적인 농도로 함유하며, 이때, 상기 길항물질은 혈액-뇌장벽 및 혈액-망막 장벽을 통과할 수 있는 제조 방법.
  4. 인간환자에서 녹내장 관련 손상에 대해 망막 신경절 세포를 보호하는 약의 제조 방법으로서, 이 약은 글루타메이트에 의해 유도된 자극 독성의 길항물질은 상기 자극 독성을 감소시키기에 효과적인 농도로 함유하며, 이때, 상기 길항물질은 L-형 전위 의존성 Ca++채널에 직접적인 효과를 거의 미치지 않는 것을 특징으로 하는 방법.
  5. 제2항 또는 제4항에 있어서, 상기 길항물질이 혈액-뇌 장벽 및 혈액-망막 장벽을 통과할 수 있는 방법.
  6. 제1항 내지 제4항중 어느 한항에 있어서, 상기 녹내장이 만성 폐색 각(chronicclosed-angle) 녹내장인 방법.
  7. 제1항 내지 제4항중 어느 한항에 있어서, 상기 녹내장이 원발 개방각(primary open-angle) 녹내장인 방법.
  8. 제1항 내지 제4항중 어느 한항에 있어서, 상기 녹내장이 가수정체 박리(pseudoexfoliation) 녹내장인 방법.
  9. 제2항 또는 제4항에 있어서, 상기 길항 물질이 혈액-뇌 및 혈액-망막 장벽을 통과할 수 있는 방법.
  10. 제1항 내지 제4항중 어느 한항에 있어서, 상기 약을 상기 환자에게 구소적으로 투여하는 방법.
  11. 제1항 내지 제4항중 어느 한항에 있어서, 상기 약을 상기 환자에게 경구적으로 투여하는 방법.
  12. 제1항 내지 제4항중 어느 한항에 있어서, 상기 약을 상기 환자에게 초자체내로 투여하는 방법.
  13. 제1항 내지 제4항중 어느 한항에 있어서, 상기 길항 물질이 NMDA 수용기-채널 복합체의 길항 물질인 방법.
  14. 제1항 내지 제4항중 어느 한항에 있어서, 상기 길항 물질이 NMDA 수용기 채널 복합체를 통해 작동하지 않는, 글루타메이트에 의해 유도된 자극 독성의 길항 물질인 방법.
  15. 제1항 내지 제4항중 어느 한항에 있어서, 상기 길항물질이 표2에 나열한 것들중 하나인 방법.
  16. 제1항 내지 제4항중 어느 한항에 있어서, 상기 약을 장기적으로 투여하는 방법.
  17. 제1항 또는 제2항에 있어서, 상기 약이 표2에 나열한 글루타메이트 자극 독성의 길항 물질을 표3, 표4 또는 표5에 나열한 글루타메이트 자극 독성의 길항 물질과 함께 함유하는 방법.
  18. 제3항 또는 제4항에 있어서, 상기 약이 표2에 나열한 글루타메이트 자극 독성의 길항 물질을 표3, 표4 또는 표5에 나열한 글루타메이트 자극 독성의 길항 물질과 함께 함유하는 방법.
  19. 제7항에 있어서, 글루타메이트 자극 독성의 상기 길항 물질이 표2에 나열한 화합물인 방법.
  20. 제8항에 있어서, 글루타메이트 자극 독성의 상기 길항 물질이 표2에 나열한 화합물인 방법.
  21. 제9항에 있어서, 글루타메이트 자극 독성의 상기 길항 물질이 표2에 나열한 화합물인 방법.
  22. 제1항 내지 제4항중 어느 한항에 있어서, 글루타메이트 자극 독성의 상기 길항 물질이 세포로부터 글루타메이트의 방출을 제한하는 화합물인 방법.
  23. 제1항 내지 제4항중 어느 한항에 있어서, 글루타메이트 자극 독성의 상기 길항 물질이 세포막 글루타메이트 수용기와 글루타메이트 상호 작용의 세포내 신경 독성의 결과를 차단하는 화합물인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702259A 1992-12-04 1993-12-06 녹내장 치료 방법(glaucoma treatment) KR960700046A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/984,939 US5922773A (en) 1992-12-04 1992-12-04 Glaucoma treatment
US07/984,939 1992-12-04
PCT/US1993/011833 WO1994013275A1 (en) 1992-12-04 1993-12-06 Glaucoma treatment

Publications (1)

Publication Number Publication Date
KR960700046A true KR960700046A (ko) 1996-01-19

Family

ID=25531050

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702259A KR960700046A (ko) 1992-12-04 1993-12-06 녹내장 치료 방법(glaucoma treatment)

Country Status (11)

Country Link
US (1) US5922773A (ko)
EP (1) EP0671910B1 (ko)
JP (2) JPH08506807A (ko)
KR (1) KR960700046A (ko)
AT (1) ATE275948T1 (ko)
AU (1) AU683634B2 (ko)
CA (1) CA2150933C (ko)
DE (1) DE69333626T2 (ko)
ES (1) ES2229213T3 (ko)
PT (1) PT671910E (ko)
WO (1) WO1994013275A1 (ko)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AU716577B2 (en) * 1994-07-06 2000-03-02 Sanofi-Aventis Use of polyamine antagonists for the treatment of glaucoma
JPH08231400A (ja) * 1995-02-24 1996-09-10 Rohto Pharmaceut Co Ltd イフェンプロジルを必須成分とする眼圧降下剤
JPH0967270A (ja) * 1995-08-31 1997-03-11 Res Dev Corp Of Japan 水晶体混濁の予防および治療法、並びにそのための薬 剤
EP0861079A1 (en) * 1995-11-17 1998-09-02 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
ES2238702T3 (es) 1995-12-21 2005-09-01 Alcon Laboratories, Inc. Utilizacion de ciertos compuestos de isoquinolinsulfonilo en el tratamiento de glaucomas y de isquemias oculares.
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ES2171233T3 (es) * 1996-01-02 2002-09-01 Sanofi Synthelabo Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico.
WO1997033582A1 (fr) * 1996-03-14 1997-09-18 Synthelabo Compositions d'antagonistes de site polyamine
US5891871A (en) * 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
CA2270119A1 (en) * 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Drugs for ameliorating ocular circulatory disorders
AU731447B2 (en) * 1996-12-16 2001-03-29 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy
US6159958A (en) * 1997-08-14 2000-12-12 The United States Of America As Represented By The Secretary Of The Army Treatment or prophylaxis of retinal pathology and spinal cord injury
AU1388999A (en) * 1997-12-16 1999-07-05 Alcon Laboratories, Inc. The use of nitric oxide generations for the treatment of dry eye disorders
WO1999042104A1 (en) * 1998-02-23 1999-08-26 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
MXPA01006449A (es) * 1998-12-24 2002-04-24 R Tech Ueno Ltd Un agente para tratar el transtorno de la funcion de las celulas visuales.
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2001010442A1 (fr) * 1999-08-09 2001-02-15 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la mort de cellules ganglionnaires de la retine
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DK1227859T3 (da) * 1999-11-12 2006-12-11 Alcon Inc Neurophilinligander til behandling af okulære tilstande
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
EP1252895A4 (en) * 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd REMEDIES FOR OPHTHALMIC DISORDERS
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2401775A1 (en) * 2000-02-29 2001-09-07 Abbot F. Clark Diagnostics and therapeutics for glaucoma
AU2001219185A1 (en) 2000-03-17 2001-10-03 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
CN1680324A (zh) * 2000-05-30 2005-10-12 奥索-麦克尼尔药品公司 二氢吡啶软药及相关组合物和方法
PT2153819E (pt) 2000-07-14 2012-11-14 Allergan Inc Utilização de um componente para aumento de solubilidade numa composição aquosa compreendendo tartarato de brimonidina
CA2429480A1 (en) * 2000-11-22 2002-05-30 Tomiya Mano Ophthalmological preparations
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
BR0210241A (pt) 2001-06-01 2004-08-10 Alcon Inc Piranoindazóis e seu uso no tratamento de glaucoma
BR0210238A (pt) 2001-06-01 2004-07-20 Alcon Inc Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
AU2003233729B2 (en) 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
WO2004058238A1 (en) * 2002-12-23 2004-07-15 Alcon, Inc. Use of cathepsin k inhibitors for the treatment of glaucoma
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
SI1614419T1 (sl) 2003-04-17 2012-12-31 Toyama Chemical Co., Ltd. Preventivno sredstvo/zdravilo za bolezni vidnega ĺ˝ivca, vsebujoäśe derivate alkil etra ali soli le-teh
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
CA2537119A1 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN1842335A (zh) 2003-09-04 2006-10-04 默克公司 用于治疗高眼压的眼用组合物
ATE425971T1 (de) 2003-09-04 2009-04-15 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
EP1773350B1 (en) * 2004-07-12 2013-05-29 Allergan, Inc. Opthalmic compositions for treating ophthalmic conditions
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP2008507557A (ja) * 2004-07-22 2008-03-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 眼疾患の治療法
BRPI0513862A (pt) * 2004-07-26 2008-05-20 Allergan Inc métodos de tratar condições oftálmicas
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
EP1885689A1 (en) * 2005-05-06 2008-02-13 Chevron U.S.A., Inc. Diamondoid derivatives possessing therapeutic activity
US20080009546A1 (en) * 2005-05-06 2008-01-10 Chevron U.S.A. Inc. Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
CA2608476A1 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US20090197930A1 (en) * 2006-02-02 2009-08-06 Kenji Yoshida Eyedrops
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
KR20100080597A (ko) * 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
KR101520086B1 (ko) * 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 １´,３´-이치환된-４-페닐-３,４,５,６-테트라히드로-２ｈ,１´ｈ-[１,４´]비피리디닐-２´-온
JP5433582B2 (ja) * 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CA2755118A1 (en) * 2009-03-10 2010-09-16 Santen Pharmaceutical Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1012870B8 (pt) 2009-05-12 2021-05-25 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CA2772877A1 (en) * 2009-09-01 2011-03-10 Lz Therapeutics, Inc. Treatment of glaucoma and other retinopathies with gangliosides
BR112012004689A2 (pt) 2009-09-01 2019-09-24 Lz Therapeutics Inc métodos para extração e purificação de gangliosídeos.
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
WO2011127151A2 (en) 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
CN102883709A (zh) 2010-04-07 2013-01-16 阿勒根公司 用于眼用制剂的防腐组合物联合
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2602654B1 (en) * 2011-12-08 2023-04-19 Essilor International Ophthalmic filter
CA2862157C (en) 2012-01-20 2016-03-22 Garnet Biotherapeutics, Inc. Methods of ganglioside production
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
KR102502485B1 (ko) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3223793B1 (en) 2014-11-25 2023-06-28 Eximore Ltd. Compositions and methods for delivering a bio-active agent or bio-active agents
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
DE3856401D1 (de) * 1987-01-23 2000-05-04 Gen Hospital Corp Hydralazin zur topischen Behandlung von Glaukom
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US5070088A (en) * 1989-12-19 1991-12-03 E. R. Squibb & Sons, Inc. Pyranyl quinoline calcium channel blockers
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
WO1993023082A1 (en) * 1992-05-13 1993-11-25 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5435998A (en) * 1994-08-03 1995-07-25 Abelson; Mark B. Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents

Also Published As

Publication number Publication date
DE69333626T2 (de) 2005-02-10
JPH08506807A (ja) 1996-07-23
AU5741494A (en) 1994-07-04
PT671910E (pt) 2004-12-31
AU683634B2 (en) 1997-11-20
CA2150933C (en) 2010-02-09
ATE275948T1 (de) 2004-10-15
ES2229213T3 (es) 2005-04-16
WO1994013275A1 (en) 1994-06-23
EP0671910B1 (en) 2004-09-15
US5922773A (en) 1999-07-13
JP2006070039A (ja) 2006-03-16
DE69333626D1 (de) 2004-10-21
CA2150933A1 (en) 1994-06-23
EP0671910A1 (en) 1995-09-20
EP0671910A4 (en) 1999-01-13

Similar Documents

Publication Publication Date Title
KR960700046A (ko) 녹내장 치료 방법(glaucoma treatment)
KUBENA et al. Interactions of Δ1-tetrahydrocannabinol with barbiturates and methamphetamine
AU617494B2 (en) Method of treatment for autoimmune diseases
DE68913650T2 (de) Antiglaukoma-zubereitungen, die kombinationen von alpha-2 agonisten und beta-blocker enthalten.
ES2146654T3 (es) Derivado de morfinano y uso medico.
De la Garza et al. Effects of haloperidol and physostigmine on self-administration of local anesthetics
NZ508526A (en) Opioid formulations for treating pain
EP1005274A4 (en) ORAL ACTIVE FACTION OF MOMORDICA CHARANTIA, THEIR ACTIVE PEPTIDES AND THEIR USE IN THE TREATMENT OF THE DIABETES
CA2205863A1 (en) Liposome eye drops
KR910019618A (ko) 발기부전증 치료용 제약 조성물
DK0904067T3 (da) Transdermalt indgivet dextromethorpan som hostestillende middel
Plotnikoff et al. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
DE3483338D1 (de) Pharmazeutische peptide, ihre herstellung und verwendung sowie zwischenprodukte.
Hjorth et al. Postsynaptic dopamine (DA) receptor stimulator properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK&F 38393
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
Drance et al. Pilocarpine and Intraocular Pressure: Duration of Effectiveness of 4% and 8% Pilocarpine Instillation
Yamaguchi et al. Itch-associated response and antinociception induced by intracisternal endomorphins in mice
WESCOE et al. STUDIES ON THE INTER-RELATIONSHIP OFCERTAIN CHOLINERGIC COMPOUNDS: I. The Pharmacology of 3-Acetoxy PhenyltrimethylammoniumMethylsulfate
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
Speizer et al. The influence of propranolol on abnormal behaviour induced in rats by prolonged isolation--an animal model for mania?
D'Amour A comparative assay of black widow anti-sera
Smith et al. Sulfones in Experimental Tuberculosis: Chemical Constitution and Chemotherapeutic Action

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20011017

Effective date: 20021226

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20030128

Effective date: 20031205

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL

J303 Written judgement (supreme court)

Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20031227

Effective date: 20060127